HARMONi-GU1: A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Sep 12, 2026 - P2/3 | N=800 | Recruiting | Sponsor: Summit Therapeutics
New P2/3 trial • Oncology • Solid Tumor • Urothelial Cancer
|